Efforts towards delineation of signalling leading to G2/M checkpoint activation may have been fuelled by the recognition that this checkpoint is essential in cells with TP53 loss and thus the potential to uncover therapeutic opportunities in TP53 negative cancers [80]. This evidence concerns the gene TP53 and cancer.